These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9731902)

  • 1. A Gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy.
    Green GA; Hanlon AL; Al-Saleem T; Hanks GE
    Cancer; 1998 Sep; 83(5):971-6. PubMed ID: 9731902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
    Zagars GK; Pollack A; von Eschenbach AC
    Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis.
    Pinover WH; Hanlon A; Lee WR; Kaplan EJ; Hanks GE
    Cancer; 1996 Apr; 77(7):1334-41. PubMed ID: 8608512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
    Valicenti RK; Chervoneva I; Gomella LG
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma.
    Algan O; Fosmire H; Hynynen K; Dalkin B; Cui H; Drach G; Stea B; Cassady JR
    Cancer; 2000 Jul; 89(2):399-403. PubMed ID: 10918172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure.
    Hanlon AL; Hanks GE
    Cancer J; 2000 Apr; 6 Suppl 2():S193-7. PubMed ID: 10803836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
    J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.